Japan approves Mitsubishi's Canalia for Type II diabetes

Last month, Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Canalia teneligliptin/canagliflozin (MT-2412) to treat Type II diabetes.

Canalia is an oral fixed-dose combination of Tenelia teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Canaglu canagliflozin, a sodium-glucose transporter 2 (SGLT2) inhibitor...